Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns: Original scientific article. ADMET and DMPK, [S. l.], p. 2956, 2025. DOI: 10.5599/admet.2956. Disponível em: https://pub.iapchem.org/ojs/index.php/admet/article/view/2956. Acesso em: 24 oct. 2025.